Prime Medicine (PRME) EBIT (2021 - 2026)

Prime Medicine (PRME) has 6 years of EBIT data on file, last reported at -$50.7 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT rose 3.32% year-over-year to -$50.7 million; the trailing twelve-month figure through Mar 2026 stood at -$206.6 million (changed 0.05% YoY), and the FY2025 full-year result was -$208.4 million, down 2.91% from the prior year.
• EBIT for Q1 2026 stood at -$50.7 million, down from -$48.6 million in the prior quarter.
• Across five years, EBIT topped out at -$19.9 million in Q1 2022 and bottomed at -$68.0 million in Q4 2023.
• The 5-year median for EBIT is -$48.6 million (2025), against an average of -$46.0 million.
• Peak annual rise in EBIT reached 35.6% in 2022, while the deepest fall reached 203.59% in 2022.
• A 5-year view of EBIT shows it stood at -$38.7 million in 2022, then tumbled by 75.89% to -$68.0 million in 2023, then jumped by 35.01% to -$44.2 million in 2024, then slipped by 9.92% to -$48.6 million in 2025, then declined by 4.21% to -$50.7 million in 2026.
• The last three EBIT figures came in at -$50.7 million (Q1 2026), -$48.6 million (Q4 2025), and -$54.0 million (Q3 2025), per Business Quant data.

Peer Comparison